A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite…

Overview of attention for article published in Arthritis Research & Therapy, July 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (80th percentile)
Above-average Attention Score compared to outputs of the same age and source (52nd percentile)

Mentioned by

news: 1 news outlet

policy: 1 policy source

Readers on

mendeley: 68 Mendeley

Summary News Policy documents

So far, Altmetric has seen 1 news story.

Equivalence of PF-06438179/GP1111 and infliximab demonstrated

medwireNews, 09 Aug 2018

09-08-2018 | Rheumatology | News | Article medwireNews: Results of a phase III trial indicate that the infliximab biosimilar PF-0…